Mioflazine

Mioflazine is an orally active nucleoside transport inhibitor with sleep-improving activity. Mioflazine significantly improves cardiac survival after global cardiac ischemia. Mioflazine inhibits nucleoside uptake Mioflazine does not exhibit inotropic effects during induction and nursing[1][2][3].

Product Specifications

CAS Number

[79467-23-5]

UNSPSC

12352005

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/mioflazine.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=C(Cl)C=CC=C1Cl)CN2CC(C(N)=O)N(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2

Molecular Formula

C29H30Cl2F2N4O2

Molecular Weight

575.48

References & Citations

[1]Wauquier A, et al. Sleep improvement in dogs after oral administration of mioflazine, a nucleoside transport inhibitor. Psychopharmacology (Berl) . 1987;91 (4) :434-9.|[2]Pirovano IM, et al. Inhibition of nucleoside uptake in human erythrocytes by a new series of compounds related to lidoflazine and mioflazine. Eur J Pharmacol. 1990 Dec 15;189 (6) :419-22.|[3]J G Hugtenburg, et al. The influence of nifedipine and mioflazine on mitochondrial calcium overload in normoxic and ischaemic guinea-pig hearts. Eur J Pharmacol. 1990 Mar 13;178 (1) :71-8.